港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

科倫博泰生物-B

300.000

+14.6005.12%

成交量：122.11萬

成交額：3.68億

市值：681.00億

市盈率：-235.14

高：308.600

開：280.000

低：278.000

收：285.400

資料載入中...

總覽公司新聞公告

招銀國際：醫保持續支持創新基金收支有望改善

港股異動 | 科倫博泰生物-B(06690)漲超3% SKB264末線TNBC獲批首款產品即將進入商業化階段

科倫博泰生物-B盤中異動股價大漲5.24%報192.800港元

國金證券：“春季躁動”或超預期前置、極致聚焦科技主題

民生證券：維持科倫博泰生物-B(06990)“推薦”評級蘆康沙妥珠單抗獲批上市

科倫博泰生物-B(06990)下跌5.56%，報185.1元/股

科倫博泰生物-B盤中異動快速下挫5.05%報186.100港元

科倫博泰生物拿下TROP2 ADC藥物；華東醫藥2款新藥獲批上市 | 醫藥早參

每日经济新闻

生物醫藥股多數走高！機構看好板塊修復空間

港股收盤(11.27) | 恒指收漲2.32% 科網、醫藥、半導體股等強勢上攻美團-W(03690)領跑藍籌

科倫博泰生物-B11月27日主力資金流入2140萬元連續3日加倉

【券商聚焦】浦銀國際首予科倫博泰生物(06990)“買入”評級稱有望在ADC浪潮中成為行業引領者

A股每日市場要聞回顧（2024-11-27）

港股生物醫藥股午後放量大漲，科倫博泰生物(06990.HK)張近10%，諾誠健華(09969.HK)漲超8.5%，百濟神

科倫博泰生物抗癌新藥獲NMPA批准上市

港股異動 | 科倫博泰生物-B(06990)午後飆升逾10% 蘆康沙妥珠單抗治療2線及以上TNBC獲批上市

科倫博泰生物－Ｂ(06990)股價上升8.146%，現價港幣$192.5

阿斯达克财经

異動解讀 | 科倫博泰生物(06990.HK)盤中大漲5.62% 新藥獲批上市及看好行業前景

首個國產ADC藥物在中國獲完全批准上市

科倫博泰生物-B(06990)：核心產品蘆康沙妥珠單抗（sac-TMT）基於OptiTROP-Breast01研究治療2線及以上TNBC獲國家藥品監督管理局批准上市

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/06990/news?page=10"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科倫博泰生物-B","latestPrice":300,"timestamp":1745309292020,"preClose":285.4,"halted":0,"volume":1221118,"delay":0,"floatShares":131000000,"shares":227000000,"eps":-1.2758334144583734,"marketStatus":"已收盤","change":14.6,"latestTime":"04-22 16:08:12","open":280,"high":308.6,"low":278,"amount":368191247,"amplitude":0.107218,"askPrice":300,"askSize":100,"bidPrice":299.8,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-1.2758334144583734,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1745371800000},"marketStatusCode":5,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":285.4,"openAndCloseTimeList":[[1745285400000,1745294400000],[1745298000000,1745308800000]],"volumeRatio":1.534504,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":131000000,"roa":"-3.41%","roe":"-9.46%","lyrEps":-1.275833,"volumeRatio":1.534504,"shares":227000000,"dividePrice":0,"high":308.6,"amplitude":0.107218,"preClose":285.4,"low":278,"week52Low":120.2,"pbRate":"19.42","psRate":"33.23","week52High":346,"institutionHeld":0,"latestPrice":300,"committee":0.818182,"eps":-1.2758334144583734,"divideRate":0,"volume":1221118,"delay":0,"ttmEps":-1.2758334144583734,"open":280,"prevYearClose":163.3,"prevWeekClose":285.4,"prevMonthClose":290.8,"prevQuarterClose":290.8,"fiveDayClose":302,"twentyDayClose":264.2,"sixtyDayClose":167.7},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2488357962","title":"招銀國際：醫保持續支持創新 基金收支有望改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2488357962","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488357962?lang=zh_tw&edition=fundamental","pubTime":"2024-12-03 15:22","pubTimestamp":1733210537,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，随着政策焦点转向刺激经济，医保基金收支状况有望大幅改善。2024年医保目录调整结果已公布，新增91种药品，医保支持创新。此外，医保局医保数据赋能商业保险公司推进的探索，未来高价创新药械或将通过医保与商业保险的协同获得更好的报销覆盖。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","06990","603259","01530","LU1969619763.USD","688235","BK1589","BK1593","LU1997245177.USD","688271","BK0251","BK0239","06978","LU0456842615.SGD","LU1997245094.SGD","01801","BK1161","LU2488822045.USD","02367","BK1574","BK0216","LU0196878994.USD","BK1583","BK1207"],"gpt_icon":0},{"id":"2488939000","title":"港股異動 | 科倫博泰生物-B(06690)漲超3% SKB264末線TNBC獲批 首款產品即將進入商業化階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2488939000","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488939000?lang=zh_tw&edition=fundamental","pubTime":"2024-12-03 09:53","pubTimestamp":1733190812,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B涨超3%，截至发稿，涨2.97%，报190.6港元，成交额1670.62万港元。中信建投证券发布研报称，公司核心产品SKB264单药用于TNBC末线治疗适应症顺利获批，首款产品即将进入商业化阶段。此外，8月19日SKB264用于EGFR-TKI及铂耐药的3L NSCLC适应症NDA获受理并纳入优先审评审批，10月31日用于EGFR-TKI耐药2L NSCLC适应症NDA获受理，均有望于25年顺利获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0890818403.SGD","IE00BZ08YR35.GBP","LU2476274308.USD","LU0196878994.USD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","BK1557","LU0431992006.USD","IE00B29SXG58.USD","LU0868486357.SGD","LU2778985437.USD","BK1607","IE00BPRC5H50.USD","LU0862451753.SGD","LU1655091616.SGD","IE00BYV24P56.USD","06690","BK1214","LU0593848301.USD","IE0034224299.USD","06990","IE00B543WZ88.USD","BK1161","LU2048586759.USD","IE0008369823.USD","LU2279701549.SGD","IE00BMCWC346.EUR"],"gpt_icon":0},{"id":"2488612742","title":"科倫博泰生物-B盤中異動 股價大漲5.24%報192.800港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488612742","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488612742?lang=zh_tw&edition=fundamental","pubTime":"2024-12-02 10:41","pubTimestamp":1733107261,"startTime":"0","endTime":"0","summary":"2024年12月02日早盘10时41分，科伦博泰生物-B股票出现波动，股价急速上涨5.24%。截至发稿，该股报192.800港元/股，成交量9.966万股，换手率0.08%，振幅5.90%。资金方面，该股资金流入1155.09万港元，流出326.98万港元。科伦博泰生物-B股票所在的生物技术行业中，整体涨幅为0.47%。科伦博泰生物-B公司简介：四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120210410198e4d53e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120210410198e4d53e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2488269763","title":"國金證券：“春季躁動”或超預期前置、極致 聚焦科技主題","url":"https://stock-news.laohu8.com/highlight/detail?id=2488269763","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488269763?lang=zh_tw&edition=fundamental","pubTime":"2024-12-02 06:36","pubTimestamp":1733092570,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，12月行业配置上，期待“春季躁动”，重视科技主题机会。“春季躁动”有望提前开启，上涨斜率有望超市场预期。2025Q1宽货币+信用底部回升，市场风险偏好修复，“春季躁动”适合成长主题：AI产业与国家安全。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1218656.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0276","06990","600109","BK0201","BK0012","BK0028","BK0188","BK1161","LU0196878994.USD","BK0183"],"gpt_icon":0},{"id":"2486398564","title":"民生證券：維持科倫博泰生物-B(06990)“推薦”評級 蘆康沙妥珠單抗獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2486398564","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486398564?lang=zh_tw&edition=fundamental","pubTime":"2024-11-28 17:14","pubTimestamp":1732785251,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，民生证券发布研究报告称，维持科伦博泰生物-B“推荐”评级，预计2024~2026年科伦博泰总营业收入分别为19.93亿元、20.26亿元、30.85亿元;归母净利润分别为-1.38亿元、-6.18亿元、-1.33亿元。民生证券主要观点如下：芦康沙妥珠单抗首发适应症三线TNBC获批上市。11月27日，科伦博泰发布公告，公司核心产品TROP2 ADC芦康沙妥珠单抗或国家药监局批准上市，用于治疗既往至少接受过2种系统治疗的不可切除的局部晚期或转移性三阴性乳腺癌成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","06990"],"gpt_icon":0},{"id":"2486379339","title":"科倫博泰生物-B(06990)下跌5.56%，報185.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2486379339","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486379339?lang=zh_tw&edition=fundamental","pubTime":"2024-11-28 09:54","pubTimestamp":1732758848,"startTime":"0","endTime":"0","summary":"11月28日，科伦博泰生物-B(06990)盘中下跌5.56%，截至09:54，报185.1元/股，成交1332.09万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司，主要以抗体药物偶联物（ADC）的技术平台为基础，致力于解决全球普遍或难以治疗的癌症以及众多患人医疗需求未满足的其他疾病。公司拥有完善的一体化药物开发机制，已建立包含研发、生产、质量控制及商业化等全面功能的一体化能力，并有30多款差异化且具有临床价值的资产管线，其中10余款处于临床阶段。截至2024年中报，科伦博泰生物-B营业总收入13.83亿元、净利润3.1亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/28095445781132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2486433923","title":"科倫博泰生物-B盤中異動 快速下挫5.05%報186.100港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486433923","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486433923?lang=zh_tw&edition=fundamental","pubTime":"2024-11-28 09:54","pubTimestamp":1732758844,"startTime":"0","endTime":"0","summary":"2024年11月28日早盘09时54分，科伦博泰生物-B股票出现波动，股价急速跳水5.05%。截至发稿，该股报186.100港元/股，成交量6.98万股，换手率0.05%，振幅5.77%。资金方面，该股资金流入551.856万港元，流出611.624万港元。科伦博泰生物-B股票所在的生物技术行业中，整体跌幅为0.16%。科伦博泰生物-B公司简介：四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112809540498e450ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112809540498e450ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2486038268","title":"科倫博泰生物拿下TROP2 ADC藥物；華東醫藥2款新藥獲批上市 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2486038268","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486038268?lang=zh_tw&edition=fundamental","pubTime":"2024-11-28 07:57","pubTimestamp":1732751832,"startTime":"0","endTime":"0","summary":"NO.2 华东医药卵巢癌新药和自免新药同日获批上市11月27日，华东医药发布公告，全资子公司杭州中美华东制药有限公司收到国家药督局核准签发的《药品注册证书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128075844abe455db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128075844abe455db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","09939","06990","BK1515","BK1161","BK1574"],"gpt_icon":0},{"id":"2486842079","title":"生物醫藥股多數走高！機構看好板塊修復空間","url":"https://stock-news.laohu8.com/highlight/detail?id=2486842079","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486842079?lang=zh_tw&edition=fundamental","pubTime":"2024-11-27 18:37","pubTimestamp":1732703861,"startTime":"0","endTime":"0","summary":"11月27日，港股多数生物医药股走强。其中，科伦博泰生物-B(06990.HK)大涨10.11%，诺诚健华(09969.HK)涨8.93%，荃信生物-B（02509.HK）涨8.57%，科济药业-B（02171.HK）涨7.73%，百济神州（06160.HK）涨7.21%，金斯瑞生物科技（01548.HK）涨4.96%。","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202411_1/1cfe0a94-093d-40f9-9aa9-6ac7e40e346c.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202411_1/1cfe0a94-093d-40f9-9aa9-6ac7e40e346c.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/6746f675bde0b3216fc904f4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["BK1576","US3Y.BOND","HK0000934320.USD","BK1500","LU1969619763.USD","SH","02171","LU2328871848.SGD","US2Y.BOND","06160","BK4581","US30Y.BOND","BK4588","BK1587","US6M.BOND","06990","BK1574","BK1141","BK4504","HK0000306701.USD","IVV","SDS","ESmain","LU0588546209.SGD","SPXU","09969","SPY","SSO","US12M.BOND","BK1583","01548","HK0000306685.HKD","BK4585","OEF",".SPX","OEX","US7Y.BOND","02509","BK4550","HK0000320223.HKD","BK1161","US10Y.BOND","FOMC","UPRO","BK4077","US5Y.BOND","BK4534","BK1588","BK1585","LU0196878994.USD"],"gpt_icon":0},{"id":"2486672817","title":"港股收盤(11.27) | 恒指收漲2.32% 科網、醫藥、半導體股等強勢上攻 美團-W(03690)領跑藍籌","url":"https://stock-news.laohu8.com/highlight/detail?id=2486672817","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486672817?lang=zh_tw&edition=fundamental","pubTime":"2024-11-27 16:34","pubTimestamp":1732696483,"startTime":"0","endTime":"0","summary":"截止收盘，恒生指数涨2.32%或443.93点，报19603.13点，全日成交额1389.12亿港元；恒生国企指数涨2.57%，报7027.4点；恒生科技指数涨3.61%，报4374.44点。蓝筹股表现美团-W领跑蓝筹。截至收盘，涨7.24%，报176.2港元，成交额71.67亿港元，贡献恒指114.33点。截至11月26日14时预约结束，华为Mate 70和Mate X6 两部手机预订总量合计超450万台。黄志达股权权益由11.87%增至12.26%。截至收盘，涨12.55%，报5.92港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1216579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MCHmain","LU0359201612.USD","LU0918141705.HKD","HSCEI","LU0011963245.USD","LU2097828474.EUR","LU0708995583.HKD","LU0821914370.USD","LU0359201885.HKD","LU0672654166.SGD","LU0348816934.USD","07226","LU2488822045.USD","LU0456827905.SGD","LU2097828631.EUR","06990","02833","01385","LU0588546209.SGD","LU1008478684.HKD","YANG","03690","MPNGY","LU0320764755.SGD","02498","159582","LU0140636845.USD","LU1048596156.SGD","02443","LU0348788117.USD","513600","LU0348827113.USD","LU0499858438.USD","SG9999002562.SGD","IE0032431581.USD","HHImain","LU1251922891.USD","LU1152091754.HKD","LU0345776255.USD","LU0029875118.USD","09939","HSTECH","LU1770034418.SGD","LU0823426480.USD","00345","LU0650527681.SGD","HSI","LU0417516902.SGD","LU0348825331.USD","159938"],"gpt_icon":1},{"id":"2486812193","title":"科倫博泰生物-B11月27日主力資金流入2140萬元 連續3日加倉","url":"https://stock-news.laohu8.com/highlight/detail?id=2486812193","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486812193?lang=zh_tw&edition=fundamental","pubTime":"2024-11-27 16:16","pubTimestamp":1732695373,"startTime":"0","endTime":"0","summary":"11月27日, 科伦博泰生物-B股价涨10.11%，报收196.00元，成交金额2.09亿元，换手率0.84%，振幅8.09%，量比2.90。科伦博泰生物-B今日主力资金净流入2140万元，连续3日净流入，上一交易日主力净流入1153万元，今日环比增加85.60%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为58.33%，平均涨幅为3.36%。该股近5个交易日上涨13.60%，主力资金累计净流入2920万元；近20日主力资金累计净流入2729万元，其中净流入天数为11日。该股主力净额占比0.08%，港股市场排名70/2645。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127161643abe2b310&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127161643abe2b310&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2486812777","title":"【券商聚焦】浦銀國際首予科倫博泰生物(06990)“買入”評級 稱有望在ADC浪潮中成為行業引領者","url":"https://stock-news.laohu8.com/highlight/detail?id=2486812777","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486812777?lang=zh_tw&edition=fundamental","pubTime":"2024-11-27 16:05","pubTimestamp":1732694734,"startTime":"0","endTime":"0","summary":"首次覆盖科伦博泰生物、恒瑞医药、药明合联，均给予“买入”评级，目标价分别为230港元、人民币61元、35港元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1948520","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","06990","ADC"],"gpt_icon":0},{"id":"2486816366","title":"A股每日市場要聞回顧（2024-11-27）","url":"https://stock-news.laohu8.com/highlight/detail?id=2486816366","media":"金十数据","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486816366?lang=zh_tw&edition=fundamental","pubTime":"2024-11-27 15:23","pubTimestamp":1732692221,"startTime":"0","endTime":"0","summary":"1—10月份，规模以上工业企业中，国有控股企业实现利润总额18530.9亿元，同比下降8.2%；股份制企业实现利润总额43718.5亿元，下降5.7%；外商及港澳台投资企业实现利润总额14559.0亿元，增长0.9%；私营企业实现利润总额16501.7亿元，下降1.3%。因此比亚迪对供应商所供货产品提出要求，即从2025年1月1日起降价10%。欣旺达称，针对此次事件中的个别情况，已与员工进行了深入沟通，并通过协商达成了双方均满意的解决方案，确保了问题的妥善解决。","market":"hk","thumbnail":"https://img.jin10.com/mp/24/10/Qpe8yx4lGmKT-5yX1v1l2.jpg/lite","type":0,"news_type":0,"thumbnails":["https://img.jin10.com/mp/24/10/Qpe8yx4lGmKT-5yX1v1l2.jpg/lite"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=154491&type=news&data_type=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"xnew_highlight","symbols":["LU0196878994.USD","BK4080","06990","BK4231","BK1161","ADC"],"gpt_icon":0},{"id":"2486131668","title":"港股生物醫藥股午後放量大漲，科倫博泰生物(06990.HK)張近10%，諾誠健華(09969.HK)漲超8.5%，百濟神","url":"https://stock-news.laohu8.com/highlight/detail?id=2486131668","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486131668?lang=zh_tw&edition=fundamental","pubTime":"2024-11-27 15:16","pubTimestamp":1732691817,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["07226","LU1064131003.USD","06160","300347","LU0196878994.USD","BK0239","LU0307460666.USD","BK4139","09995","YANG","BK1576","161726","BK4505","BK0028","BK1161","LU0588546209.SGD","BK1588","BK1583","399441","LU2328871848.SGD","BK0216","BK4548","02268","BK1141","BK4585","LU1820825898.SGD","03347","LU2148510915.USD","LU1146622755.USD","HSCEI","688428","BK1574","LU1064130708.USD","06990","BGNE","BK4588","SG9999014674.SGD","HSTECH","BK0077","BK4526","LU1969619763.USD","BK0174","09969","688235","BK4535","688331","BK4504","BK1500"],"gpt_icon":0},{"id":"2486894363","title":"科倫博泰生物抗癌新藥獲NMPA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2486894363","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486894363?lang=zh_tw&edition=fundamental","pubTime":"2024-11-27 13:39","pubTimestamp":1732685940,"startTime":"0","endTime":"0","summary":"财中社11月27日电科伦博泰生物-B 发布公告，宣布公司首款用于治疗不可切除的局部晚期或转移性三阴性乳腺癌的抗体药物偶联物芦康沙妥珠单抗已获得国家药品监督管理局批准上市。作为公司的核心产品，芦康沙妥珠单抗针对多种晚期实体瘤，并具有自主知识产权。此外，公司已向NMPA递交了两项补充新药申请，分别针对EGFR突变非小细胞肺癌患者的治疗。公告提醒股东及潜在投资者，芦康沙妥珠单抗的最终商业化成功并非确定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127134654abe264ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127134654abe264ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2486457891","title":"港股異動 | 科倫博泰生物-B(06990)午後飆升逾10% 蘆康沙妥珠單抗治療2線及以上TNBC獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2486457891","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486457891?lang=zh_tw&edition=fundamental","pubTime":"2024-11-27 13:34","pubTimestamp":1732685699,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B(06990)午后飙升逾10%，截至发稿，涨5.34%，报187.5港元，成交额1.14亿港元。消息面上，科伦博泰生物午间公布，旗下抗体药物偶联物(ADC)芦康沙妥珠单抗(sac-TMT)获国家药品监督管理局批准于中国上市。据介绍，相关药物针对治疗乳腺癌(BC)、胃癌(GC)、妇科肿瘤等晚期实体瘤。另外，中国国家药监局早前已受理两项补充新药申请，分别是芦康沙妥珠单抗(sac-TMT)单药治疗经EGFR-TKI治疗后进展，或经EGFR-TKI和含铂化疗治疗后进展的局部晚期，或转移性EGFR突变非小细胞肺癌(NSCLC)患者的申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1216463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2486899297","title":"科倫博泰生物－Ｂ(06990)股價上升8.146%，現價港幣$192.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2486899297","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486899297?lang=zh_tw&edition=fundamental","pubTime":"2024-11-27 13:00","pubTimestamp":1732683600,"startTime":"0","endTime":"0","summary":"[上升股]科伦博泰生物－Ｂ(06990) 股价在下午01:00比前收市价上升8.146%，现股价为港币$192.5。至目前为止，今日最高价为$192.5，而最低价为$181.9。总成交量为39.107万股，总成交金额为港币$7.286千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR241127830/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"1117014278","title":"異動解讀 | 科倫博泰生物(06990.HK)盤中大漲5.62% 新藥獲批上市及看好行業前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1117014278","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117014278?lang=zh_tw&edition=fundamental","pubTime":"2024-11-27 12:26","pubTimestamp":1732681594,"startTime":"0","endTime":"0","summary":"科伦博泰生物(06990.HK)今日盘中大涨5.62%,引起市场关注。\n\n一方面,公司旗下的抗体药物偶联物(ADC)芦康沙妥珠单抗(sac-TMT)获国家药品监督管理局批准于中国上市,用于治疗乳腺癌、胃癌、妇科肿瘤等晚期实体瘤。随着新药上市,有望推动公司业绩持续增长,令市场对其长期前景更加看好。\n\n另一方面,国金证券发布研报称,展望2025年,创新药和仿创药的赛道性机会以及部分细分领域中个股的景气度反转,都将带来机遇。科伦博泰生物正是该行获重点推荐的标的之一。分析人士预计随着政策利好以及需求复苏,医药板块将迎来反转。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 科伦博泰生物(06990.HK)盘中大涨5.62% 新药获批上市及看好行业前景","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06990"],"gpt_icon":0},{"id":"2486882895","title":"首個國產ADC藥物在中國獲完全批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2486882895","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486882895?lang=zh_tw&edition=fundamental","pubTime":"2024-11-27 12:25","pubTimestamp":1732681557,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["399441","ADC.AU","06990","LU0196878994.USD","BK7095","BK4080","BK1161","ADC","BK4231","161726"],"gpt_icon":0},{"id":"2486958508","title":"科倫博泰生物-B(06990)：核心產品蘆康沙妥珠單抗（sac-TMT）基於OptiTROP-Breast01研究治療2線及以上TNBC獲國家藥品監督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2486958508","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486958508?lang=zh_tw&edition=fundamental","pubTime":"2024-11-27 12:21","pubTimestamp":1732681300,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 发布公告，公司首款用于既往至少接受过2种系统治疗的不可切除的局部晚期或转移性三阴性乳腺癌成人患者的国产靶向人滋养细胞表面抗塬2的抗体药物偶联物芦康沙妥珠单抗(佳泰莱)获国家药品监督管理局批准于中国上市。此前，NMPA已经受理了两项补充新药申请，分别是芦康沙妥珠单抗单药治疗经EGFR-TKI治疗后进展或经EGFR-TKI和含铂化疗治疗后进展的局部晚期或转移性EGFR突变非小细胞肺癌患者的申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1216458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"盤後","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"盤後","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2941,"buy":0.7059,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7059,"analysts":17,"updateTime":1744819200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-04-17","current":-228.611836,"percent":0.03653,"low":-257.850518,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"high":-21.029201,"avg":-97.473315,"sd":62.021902,"marketCap":64862287200},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200}],"updateTime":1745295485446}}}